Payment overview · 2025
General Payments
$1,306.80
60 reported records · 18 companies
Healthcare provider profile · identity verified
Shiela Williams, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · VINITA, OK · NPI 1750755112
Verified facts
What the public records show
CMS Open Payments records show Shiela Williams, APRN received $1,306.80 in general payments during 2025 across 60 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $216.60 | 16.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $207.54 | 15.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $157.35 | 12.0% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $112.53 | 8.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.03 | 6.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.48 | 5.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.71 | 5.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.41 | 4.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $50.93 | 3.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.72 | 3.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.05 | 3.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.90 | 3.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.89 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.34 | 2.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.50 | 2.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.18 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.71 | 1.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.93 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,268.26 | 59 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $246.44 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $216.60 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $143.95 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $122.14 | 5 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $121.09 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.03 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $70.19 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.71 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $53.41 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.72 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.05 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.64 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.64 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.34 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 372 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 59 |
| Lisinopril | Lisinopril | 304 | 54 |
| Gabapentin | Gabapentin | 244 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 49 |
| Potassium Chloride | Potassium Chloride | 221 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 34 |
| Furosemide | Furosemide | 153 | 40 |
| Metformin Hcl | Metformin Hcl | 127 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 37 |
| Losartan Potassium | Losartan Potassium | 124 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 26 |
| Meloxicam | Meloxicam | 111 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 16 |
| Trazodone Hcl | Trazodone Hcl | 100 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 20 |
| Linzess | Linaclotide | 93 | 18 |
| Baclofen | Baclofen | 88 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 21 |
| Ozempic | Semaglutide | 82 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 27 |
| Pregabalin | Pregabalin | 78 | 13 |
| Montelukast Sodium | Montelukast Sodium | 77 | 13 |
| Buspirone Hcl | Buspirone Hcl | 75 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 19 |
| Mounjaro | Tirzepatide | 71 | suppressed |
| Belsomra | Suvorexant | 70 | suppressed |
| Eliquis | Apixaban | 70 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 15 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 64 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 19 |
| Fenofibrate | Fenofibrate | 63 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | suppressed |
| Prednisone | Prednisone | 62 | 48 |
| Carvedilol | Carvedilol | 60 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | suppressed |
| Famotidine | Famotidine | 54 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 54 | suppressed |
| Trulicity | Dulaglutide | 53 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 14 |
| Ondansetron Odt | Ondansetron | 51 | 16 |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Alprazolam | Alprazolam | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | suppressed |
| Simvastatin | Simvastatin | 48 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 12 |
| Ibuprofen | Ibuprofen | 45 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | suppressed |
| Naproxen | Naproxen | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Nystatin | Nystatin | 39 | 20 |
| Tramadol Hcl | Tramadol Hcl | 37 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Estradiol | Estradiol | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 19 |
| Risperidone | Risperidone | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Finasteride | Finasteride | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Aristada | Aripiprazole Lauroxil | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Depakote Sprinkle | Divalproex Sodium | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Zafemy | Norelgestromin/Ethin.Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,306.80 · 60 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BEVESPI AEROSPHERE, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FANAPT, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UZEDY, VERQUVO, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error